Nathan Wilds, MD
Critical Care Medicine · Memphis, TNNPI 1285869503
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by GSK at 60.0% of the total. Reporting peaked in 2019 at $6,852 and has fallen 91.6% since, to $574 in 2025. Among critical care medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $92.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- Intuitive Surgical$4K
- Pulmonx Corporation$998
- AstraZeneca$439
- Boehringer Ingelheim$232
- Insmed, Inc.$177
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$10,90056%
- Travel & lodging$1,96510%
- Food & beverage$3,45818%
- Education$3,02216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 63 | $11,604 |
| Intuitive Surgical | 9 | $4,180 |
| Pulmonx Corporation | 2 | $998 |
| AstraZeneca | 24 | $439 |
| Boehringer Ingelheim | 15 | $232 |
| Insmed, Inc. | 8 | $177 |
| Mylan Specialty L.p. | 11 | $163 |
| United Therapeutics Corporation | 6 | $144 |
| Sanofi | 6 | $136 |
| Inari Medical, Inc. | 1 | $133 |
| Genentech USA, Inc. | 7 | $113 |
| Merck | 7 | $112 |
| Electromed, Inc. | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Grifols USA, LLC | 5 | $98 |
| Olympus America Inc. | 1 | $88 |
| Actelion Pharmaceuticals US, Inc. | 5 | $77 |
| Harmony Biosciences LLC | 4 | $73 |
| Verona Pharma, Inc. | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| AbbVie(2 entities) | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 4 | $38 |
| Amgen | 2 | $29 |
| La Jolla Pharmaceutical Company | 2 | $28 |
| CSL Behring | 1 | $23 |
| Bioxcel Therapeutics, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Inogen, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Gilead | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$11,003
- Da Vinci Surgical System$4,001
- Pulmonx Endobronchial Valve EBV$998
- FlowTriever$133
- ClotTriever$133
How this compares
$19,345 in reported general payments places this provider in the 95th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 202 | $169,364 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $36,106 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $34,742 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $30,873 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,301 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,736 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 174 | $4,146 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $3,828 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,525 |
| Ventolin HfaAlbuterol Sulfate | 37 | $2,782 |
| Montelukast Sodium | 46 | $499 |
| Prednisone | 51 | $251 |
| Azithromycin | 29 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $11,604 | $240,578346 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $439 | $39,47858 claims |
| Boehringer IngelheimCombivent Respimat | $232 | $7,30111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Paul DeatonMemphis$10K
- Garrettson EllisMemphis$9K
- Roy FoxMemphis$9K
- Matthew MabieMemphis$7K
- Steven WoodsMemphis$6K
- William RichardsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.